Since PPARγ activation also decreases STAT5 expression in CML stem/progenitor cells, it was hypothesised that a concurrent reduction in STAT5 could counteract the effect of decreased OCT-1 activity. This evidence concerns the gene STAT5A and chronic myelogenous leukemia, BCR-ABL1 positive.